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Report on the 2018 Cancer, Autoimmunity, and
Immunology Conference
Colleen S. Curran,* Connie L. Sommers,† Howard A. Young,‡ Katarzyna Bourcier,x
Marie Mancini,{ and Elad Sharon‖
With the increased use of cancer immunotherapy, a
number of immune-related adverse events (irAEs) are
being identified. These irAEs can be compared with
known autoimmune disorders in similar tissues, with
important similarities and differences. Understanding
the etiology of irAEs may bring to light concepts applicable to immune responses in cancer, autoimmunity,
and infectious disease. This immunobiology is especially relevant to cancer patients with preexisting allogeneic transplants or autoimmune disease who are
undergoing cancer immunotherapy. To address these
facets of cancer immunotherapy, academic leaders from
these various disciplines discussed current irAE basic
and clinical research, irAE diagnosis and management,
and the need for biomarkers and algorithms to identify
individuals at risk for irAEs at a conference jointly sponsored by the National Cancer Institute, National Institute of Allergy and Infectious Diseases, and National
Institute of Arthritis and Musculoskeletal and Skin Diseases in Bethesda, MD, on March 22–23, 2018. Mechanisms and models to characterize irAEs, standardize
protocols, store biospecimens, and capture and analyze
irAE data were also reviewed during the inaugural
Cancer, Autoimmunity, and Immunology Conference.
This summary highlights cancer immunotherapy–
induced irAEs, the challenges ahead, and the opportunities for greater understanding of autoimmune
conditions. The Journal of Immunology, 2019, 202:
2823–2828.

immune-related adverse events (irAEs) that accompany cancer
immunotherapy. After an introduction to the recent history
of cancer immunotherapy and the definition and recognition
of irAEs by Anthony Fauci (National Institute of Allergy
and Infectious Diseases [NIAID]), Dr. Topalian focused on
irAEs that result from immune checkpoint blockade therapy.
She described how T cells are activated by signal 1 (through
the T cell Ag receptor) and signal 2 (through coreceptors).
Checkpoint molecules expressed on the surface of T cells (such
as PD-1 and CTLA-4) normally restrain the T cell activation
response from becoming too long or out of control. Drugs such
as nivolumab (anti–PD-1) and ipilimumab (anti-CTLA4)
interfere with that control in a process commonly referred to as
“releasing the brakes” on T cells. Dr. Topalian discussed how
different immune checkpoint inhibitors have different mechanisms of action and different frequencies of associated irAEs.
Studies of the etiology of irAEs could help elucidate mechanisms of antitumor activity, as irAE frequency tends to
associate with higher antitumor response.
As noted by Dr. Bluestone, these irAEs may also provide
deeper understanding of the basic immunological mechanisms
underlying autoimmune conditions. The cross-talk among these
specialties has enormous potential for reverse translation in the
fields of cancer, autoimmunity, and immunology. Continued
research into the basic biological responses to immune checkpoint inhibitors and other forms of immunotherapy is needed
to further define the mechanisms of action, diagnosis, treatment,
and management of distinct irAEs that are now being observed
in clinical trials and standard oncology practice.
Murine models of irAEs

eynote speakers Suzanne Topalian (Johns Hopkins
University) and Jeffrey Bluestone (Parker Institute
for Cancer Immunotherapy [PICI] and University
of California–San Francisco) introduced each of the morning sessions of the 2-day conference that detailed the biology,
diagnosis, treatment, management, and the implications of
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Although human irAEs are not completely reproducible in
mice, a number of models have been developed that add to
our knowledge of immunotherapy-induced irAEs. Keynote
speaker Jeffrey Bluestone emphasized that in the future, we
should attempt to predict which drug combinations will
provide robust antitumor effects without irAEs, provided
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that well-characterized syngeneic mouse models can be developed. Further, it will be important for clinicians to choose
the best combination for patients who may be predisposed to
different subclinical autoimmune conditions and may develop
particular irAEs. Different mouse models with distinct autoimmune tendencies can shed light on these issues. Wild-type
mice can also be useful for immunotherapy research, as
evidenced by the work of Patrizio Caturegli (Johns Hopkins
University). His studies in wild-type mice revealed the expression of CTLA-4 in the pituitary, which provides the likely
mechanistic basis for the hypophysitis that can occasionally
develop in patients undergoing anti–CTLA-4 immunotherapy
(1) (Fig. 1A). Mice with genetic deletion of CTLA-4, PD-1,
and/or PD-L1 have revealed defects in T cell tolerance and
display various degrees of autoimmunity. As explained by
Javid Moslehi (Vanderbilt University), myocarditis occurs
in CTLA-42/2 mice crossed with PD-L12/2 or PD-12/2
mice (2), suggesting that combination therapies may increase
the risk for the development of myocardial inflammation
(Fig. 1B). IFN-g–induced PD-L1 expression on mouse heart
endothelial cells and the enhanced specific-targeted CTL
killing of these cells in the presence of anti–PD-L1 Abs was
described by Andrew Lichtman (Harvard University). Mice
with genetic tendencies toward autoimmunity (e.g., NOD
mice that develop spontaneous type 1 diabetes) are also useful
for immune checkpoint inhibitor studies. Jeffrey Bluestone
and Kevan Herold (Yale University) described a rapid onset
of type 1 diabetes in response to PD-1 or PD-L1, but not
CTLA-4, blockade in NOD mice. Mechanisms of CD81
T cell destruction of normal tissues are currently being pursued in this model. Kristina Howard (Food and Drug Administration [FDA]) described a number of immunodeficient
mouse strains with “humanized” immune systems that are
being used to test the dosing of drugs in combination, dosing route, frequency, study duration, pharmacokinetics, and
Fc receptor responses. Understanding the degree of humanization is important. For example, humanized mice retain
mouse tissue that secretes murine cytokines and chemokines
that may not be recognized by human immune cells. Each of
these various mouse models can be examined for nontarget
responses associated with bacteria or viruses that alter immune
checkpoint inhibitor–induced responses and affect patients
undergoing therapy. For example, Daniel Barber (NIAID)
described the mechanisms underlying fatal T cell–mediated
immunopathology during Mycobacterium tuberculosis infection
in PD-12/2 mice. Barber et al. (3) later studied two patients
with cancer who developed active tuberculosis during PD-1
blockade therapy for their cancers. Using longitudinal samples
from one of the patients treated on a National Cancer Institute (NCI)–sponsored trial for Merkel cell cancer, the
study team was able to show that the adverse event in this
patient mirrored the previously published murine data (3).
Retrieving the maximum amount of relevant information
from these various mouse models and understanding their
limitations is important in understanding the therapeutic
implications from these preclinical efforts.
Biological analysis of patient tumors and lymphocytes associated
with irAEs

Collection and evaluation of clinical and biological information from patients are needed to understand the development

of immune-related toxicity in specific organs. In identifying
genetic signatures of immune cells, tumor cells, and stromal
cells in the tumor microenvironment, researchers may effectively predict responders, nonresponders, and/or patient
subsets susceptible to irAEs from patient biopsies. One
approach, as described by both Emanual Maverakis (University
of California–Davis) and Orit Rozenblatt-Rosen (Broad
Institute), involves cross-comparing RNA sequencing data
obtained from tumor samples from patients who have either responded or failed to respond to immune checkpoint
blockade with bulk gene expression data from samples
uploaded in The Cancer Genome Atlas. Researchers can
also compare the gene signatures retrieved from autoimmune
and cancer patients. David Hafler (Yale University) provided
an example of melanoma patients with a BRAFV600K mutation
that may develop myelin-autoreactive T cells subsequent to
anti–CTLA-4 therapy, similar to T cells found in multiple
sclerosis patients (4). Ignacio Sanz (Emory University) indicated that next-generation sequencing of TCRs and BCRs, as
well as integrated transcriptome and epigenome differential
and comparative analyses, may yield strategies for diagnostics
and therapeutics. Systematic pipelines for profiling are being
established in association with computational tools to better
handle the data with the goal of generating a “tumor cell
atlas,” similar to the international Immune Cell Atlas that
is already in progress. To enable future efforts at immune
profiling patients enrolled on NCI-sponsored clinical trials, the NCI is also funding a network of Cancer Immune
Monitoring and Analysis Centers (CIMACs) and a Cancer
Immunologic Data Commons (CIDC). As described by
Sacha Gnjatic (Icahn School of Medicine at Mount Sinai),
the CIMAC-CIDC network (https://cimac-network.org) is
establishing multidisciplinary working groups to analyze
tissue samples, blood, serum, and stool from both pre- and
posttherapy specimens. The effort is focused mostly on improving therapeutic efficacy, but this approach can be easily
adapted for the continued exploration of the biology of tumors and irAEs in patients to help identify and characterize
biomarkers to prevent, diagnose, and treat irAEs.
irAE risk factors, diagnosis, and management

The number of irAEs occurring as the result of cancer immunotherapy is likely underestimated because of delayed
onset, death, and a lack of adequate monitoring after treatment cessation. These irAEs may develop in virtually any tissue
in the body (5) (Fig. 1). Although the identification and
management of irAEs is primarily drawn from experience
with similar autoimmune disorders, irAEs are distinct in
their pathogenesis, suggesting that their treatments may
also differ. Methods to identify risk factors and diagnose,
treat, and manage irAEs are only beginning to be realized
as experience accrues with time.
A variety of relevant risk factors are being explored in the
development of irAEs. In the case of immune checkpoint
inhibitor–induced skin toxicities, UV radiation may also be
a factor, as described by Nicole LeBoeuf (Dana-Farber Cancer
Institute). Pathogens as well as a genetic predisposition may
stimulate the expression of PD-L1 on the surface of cells
(Fig. 1). Kevan Herold (Yale University) stated that immune
checkpoint inhibitor–induced, insulin-dependent diabetes can
occur, with a family history of autoimmunity as a possible risk
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FIGURE 1. Identified immune checkpoint inhibitor (ICI)–induced toxicities. (A) ICI-induced hypophysitis. Ab blockade of pituitary cell CTLA-4 promotes
the activation of the classical complement cascade (C1q) and recruitment of macrophages for targeted phagocytic engulfment of CTLA-41 pituitary cells.
Radiographic imaging and consultation with an endocrinologist can lead to early diagnosis and reduce treatment morbidity. (B) ICI-induced myocarditis. Infection or genetics may encourage endothelial PD-L1 expression that is bound by CD8 T cell PD-1. This form of tolerance is abrogated by Ab blockade of the
PD-1 axis, resulting in CTL killing and inflammation. Diagnostics may include biopsy, cardiac magnetic resonance (CMR) imaging, electrocardiography (ECG),
biomarkers, symptoms of the syndrome, negative angiography, or an echocardiogram of wall-motion abnormalities (ECHO WMA). (C) ICI-induced skin
toxicities. The formation of irAEs in the skin may involve a second “hit” involving a sunburn or infection. Specific ICI therapies tend to develop distinct
skin toxicities. (D) ICI-induced rheumatoid arthritis. Two major forms of arthritis are evolving secondary to PD-1/PD-L1 monotherapy and the CTLA-4 plus
PD-1/PD-L1 combination. This irAE is poorly recognized in clinical trials, particularly when only small joints are affected. (E) ICI-induced myositis/myasthenia
gravis. Unlike the characterized autoimmune disorders, myositis and myasthenia gravis can appear together subsequent to ICIs as identified by anti-acetylcholine
(ACh) receptor (AChR) Abs and elevated creatine kinase (CK) levels. These irAEs may also occur concurrently with myocarditis. (F) ICI-induced colitis.
ICI-induced gut toxicities physically appear more similar to colitis than inflammatory bowel disease, involve neutrophil and lymphocyte recruitment, and may
occur more frequently with anti–CTLA-4 therapy.

factor. Patients with organ transplants, previous chemotherapy/
immunotherapy, or additional preexisting cardiac or autoimmune disease (Fig. 2A) may also have heightened risks
for irAEs.
Monica Girotra (Memorial Sloan Kettering Cancer Center),
Clifton Bingham (Johns Hopkins University), and Javid Moslehi
(Vanderbilt University) highlighted that the diagnosis of
irAEs is complicated by a lack of comprehensive definitions
to identify patients in need of referrals to specialists. This is
due to a lack of standardized reporting, which can result in the
underdiagnosis of conditions. Continued development of
biomarkers and diagnostic techniques for irAEs will require

strong multidisciplinary collaborations and rapid referrals to
relevant specialists.
Immunosuppressive irAE management approaches are being
drawn from experience with autoimmunity, other immunebased therapies, retrospective analyses, and prospective studies (Fig. 2B). The type of immunosuppression used should
be determined in collaboration with specialists able to evaluate the state of their autoimmune disease (active or inactive),
the degree of flares, and toxicities. Nirali Shah (NCI) described one example from the cell-based immunotherapy
field that involves the treatment of cytokine release syndrome, most notably in patients who have been treated with
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FIGURE 2. Capturing irAE data relevant to patient diversity. (A) The diversity of tumors and patient conditions is a significant factor in irAEs. The use of
immune checkpoint inhibitors requires the development of criteria to manage potential irAEs or exclude certain patient subsets. (B) As patients continue to be
treated with immune checkpoint inhibitors either in monotherapy or in combination therapies, the identification of irAEs is anticipated to grow. Managing the
data from these trials will require the development of standardized definitions and protocols that can be broadly accepted across institutions. These are the
challenges ahead.

CD19-targeting chimeric Ag receptor–T cell therapy. A
significant minority of patients experienced life-threatening
cytokine release syndrome, but the administration of anti–
IL-6R Abs (tocilizumab) was shown early in trials to ablate
this irAE while preserving the immune response to the tumor.
Establishing similar algorithms to treat and potentially prevent the development of the more commonly observed
irAEs is urgently needed. Retrospective analyses may also be
useful for developing treatment parameters. Alexander Faje
(Massachusetts General Hospital) described a recent study in
melanoma patients with ipilimumab-induced hypophysitis.
This study indicated that low-dose (#7.5 mg of prednisone)
compared with high-dose (.7.5 mg of prednisone) corticosteroid treatment may have benefits in terms of overall
survival (6). Management of irAEs may persist long after
cessation of active treatment with a particular immunotherapy regimen, in part because of prolonged activation
of the offending T cell clones, inducing the irAE (7). In
some cases (e.g., immune checkpoint inhibitor–induced
rheumatoid arthritis), the irreparable damage will require
lifelong care.
Using immunotherapy in patients with cancer in the setting of
allogeneic transplants or preexisting autoimmunity

In the absence of additional treatment options, immune
checkpoint inhibitor therapy is being considered for cancer
patients with a prior history of allogeneic transplants or preexisting autoimmunity. Typically, these patients have been
excluded from clinical trials, as the perceived risks of graftversus-host disease (GVHD) or autoimmune disease flare
were deemed to be too great. To address the treatment needs
of these patients, the NCI is sponsoring several studies in
this population with immune checkpoint inhibitor therapy.

In metastatic melanoma and metastatic cutaneous squamous
cell carcinoma patients who also had prior allogenic kidney
transplants, Evan Lipson (Johns Hopkins University) described case reports of ipilimumab and pembrolizumab
treatment, respectively, that resulted in durable partial responses for as long as 8 y and ongoing (8, 9). Although there
is a significant risk of allograft rejection, the results suggest
that immune checkpoint inhibitors can be highly effective
against cancers arising in the context of immunosuppression. To selectively activate antitumor immunity and deter
rejection, a prospective clinical trial (National Clinical Trial
Identifier: NCT03816332) assessing nivolumab with a tacrolimus and prednisone immunosuppression regimen is being
initiated in patients with advanced cancers and a preexisting
renal allograft. The objectives are focused on safety, feasibility,
and maintenance of the renal allograft. Correlative studies
are planned to help characterize immunological changes in
paired biopsies obtained pretreatment and on treatment;
assess changes in donor-derived, cell-free DNA as an early
marker for allograft rejection; and describe irAEs in these
patients.
Treatment options for allogeneic hematopoietic stem cell
transplantation (allo-HSCT) patients that experience subsequent relapse include salvage cytotoxic chemotherapy, withdrawal of immune suppression, donor lymphocyte infusion,
and a repeated allo-HSCT. Jacqueline S. Garcia (Dana-Farber
Cancer Institute) and Yvette Kasamon (FDA) described analyses
of patients who were treated with immune checkpoint inhibitors following allo-HSCT for hematologic malignancies. Ipilimumab-induced durable clinical responses were
noted in several patients with acute myelogenous leukemia
who had previously relapsed following allo-HSCT. These
occurred in association with GVHD and additional toxicities
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in a clinical trial sponsored by the NCI (10). In a retrospective
analysis of 31 patients, durable complete responses with
GVHD were also identified in patients with classical Hodgkin
lymphoma treated with anti–PD-1 therapy following alloHSCT and subsequent relapse (11). In another retrospective study, allo-HSCT after PD-1 blockade was also
considered feasible but with toxicities such as hyperacute
GVHD, hepatic veno-occlusive disease, and other irAEs,
including transplant-related mortality (12). These patients
therefore need to be followed closely for transplant-related
complications to facilitate prompt interventions. The U.S.
FDA has cited safety concerns about the administration of
immune checkpoint inhibitors before and after allo-HSCT.
Safety signals need to be further investigated to differentiate immune checkpoint inhibitor–induced toxicity from
GVHD, which will require ongoing observational studies
and long-term monitoring.
As noted, patients with preexisting autoimmunity are
generally excluded from clinical trials because of concern over
complications with the patients’ autoimmune diseases as described by Hussein Tawbi (MD Anderson Cancer Center).
Consequently, the NCI is now initiating a prospective trial
(National Clinical Trial Identifier: NCT03816345) exploring
treatment options with immune checkpoint inhibitors for this
category of patients in collaboration with multiple leading
autoimmune disease experts who will serve as coinvestigators
with the treating oncologists. The focus remains on conditions for which PD-1 and PD-L1 inhibitors have an approved
indication. Retrospective efforts have suggested that benefits
are possible with appropriate monitoring (13, 14). The initial
disease cohorts will include patients with dermatomyositis,
scleroderma, rheumatoid arthritis, systemic lupus erythematosus, inflammatory bowel disease, and multiple sclerosis. The aims are to establish safety and dose-limiting
toxicities of treatments, accurately assess the kinetics of flares
and the dynamics of other irAEs, assess antitumor response,
and identify the mechanisms of toxicity associated with
autoimmunity.
Management of irAE data and protocols

As the development and use of immunotherapies continue
to expand, strategies to record, manage, and interpret an increasing amount of information are needed to maintain relevant standards in safety and labeling (Fig. 2B). Sean Khozin
(FDA) discussed a multidisciplinary initiative to analyze adverse event reporting to the FDA, known as Information
Exchange and Data Transformation (INFORMED) (15).
The aggregation and harmonization of immune checkpoint
clinical trials data submitted to the FDA are expected to better
characterize the safety of these agents with respect to irAE
incidence, risk factors, clinical presentation, treatment, and
outcomes. These techniques can also be transferred to the
evaluation of the patient experience by examining electronic
health records. However, interpretation of these datasets is
premised on the reporting terms used by investigators and
clinicians, which can be quite variable in the reporting of
irAEs. Marc Theoret (FDA) highlighted FDA efforts to
generate a comprehensive list of adverse reaction terms,
evaluations of alternate etiologies, and the use of immunosuppressive medications from retrospective and prospective
studies to better design case-based definitions of irAEs.
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The Alliance for Clinical Trials in Oncology, in collaboration with the NCI, is developing an irAE biorepository
to help advance further translational research efforts relevant to irAEs. David Kozono (Dana-Farber Cancer Institute)
discussed the Alliance-NCI irAE Biorepository, which is a
centralized repository for acquiring and storing well-annotated
biospecimens vital for translational studies and generating data
relevant to the molecular pathogenesis and treatment of severe
irAEs. This group aims to develop retrospective and prospective protocols for the collection of data and biospecimens
from clinical trials and standard-of-care patients. Samantha
Bucktrout (PICI) described PICI pilot grants that have included preclinical, prospective, and cross-site retrospective
studies that generate data on immunotoxicity, tumor control,
and immune responses.

Conclusions
The success of cancer immunotherapy has revealed untoward
immune-related side effects that are anticipated to shed light
on the complex mechanisms involved in immunity and disease.
The use of mouse models and the extensive assessment of
patient biospecimens and clinical data are expected to identify
irAE risk factors and biomarkers that will be able to shed light
on the potential pathogenesis of cognate autoimmune diseases.
Understanding the various facets of the immune response
will be pivotal in treating patients with a diversity of tumor
types and preexisting conditions. Establishing irAE definitions and reporting standards will require multiple disciplines
and collaborations between stakeholders to effectively understand, prevent, diagnose, and treat irAEs. This will be of utmost
importance in recognizing irAEs that may arise as patients
live longer and as combination therapies and new immunotherapies are investigated in clinical trials. These topics,
additional irAEs, and their current status in clinical trials
are subjects of the second annual Cancer, Autoimmunity, and
Immunology Conference (Bethesda, MD, April 15–16, 2019).
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